Navigation Links
Experimental Drug Fails Against Heart Failure
Date:11/6/2007

Tezosentan didn't change outcomes for patients with sudden, life-threatening attacks, trial shows

TUESDAY, Nov. 6 (HealthDay News) -- An experimental kind of medication has failed as treatment for the emergency condition known as acute heart failure, a new trial finds.

The drug, tezosentan, did not improve patients' breathlessness, reduce their incidence of major cardiovascular events, or cut their risk of death after acute heart failure, concludes an international study published in the Nov. 7 issue of the Journal of the American Medical Association.

"This is an investigational new drug that is an endothelin receptor blocker," explained study co-author Dr. John R. Teerlink, an associate professor of medicine at the University of California, San Francisco.

Endothelin is "one of the most potent vasoconstrictors known," Teerlink said, meaning that it causes blood vessels to become narrower. In fact, it has similar properties to snake venom, he said.

Episodes of acute heart failure can occur in people with chronic heart failure, in which the heart slowly loses the ability to pump blood. The loss of that ability occurs suddenly in an acute episode, leaving a person gasping for breath. The lungs can fill rapidly with fluid, and the episode can be fatal.

While chronic heart failure is routinely managed with a variety of drugs, including beta blockers and fluid-reducing diuretics, "all the available agents for acute heart failure have significant side effects," Teerlink said.

Many existing medications, such as nitroglycerin, act by causing blood vessels to become wider, improving blood low. Tezosentan would act differently, by preventing blood vessels from narrowing.

In the study, more than 1,400 people who suffered episodes of acute heart failure were either given infusions of tezosentan for up to 72 hours or a placebo.

The drug did not improve breathlessness more than placebo, the researchers found. The incidence of death or worsening heart failure after seven days was 26 percent for patients in each group, and the six-month death rate was 14.3 percent for both groups.

The drug's failure to improve outcomes is a major disappointment, said Dr. Randall Starling, director of heart failure and transplantation at the Cleveland Clinic.

"The treatment of acute heart failure is clearly an area with an unmet need," Starling said. "The majority of patients with shortness of breath and congestion are treated with intravenous diuretics. There is a 10 to 12 percent death rate and a 20 percent readmission rate within 30 days. There is also serious concern among physicians that the treatment may have deleterious effect on kidney function."

But several promising drugs now are in large-scale trials, said Dr. Christopher M. O'Connor, professor of medicine and director of the heart center at Duke University in Durham, N.C. Results of one trial, which has enrolled 7,500 patients, are expected in about a year, while a second trial of another agent may become available in two to three years, he said.

And the last word on tezosentan may not yet have been spoken, Teerlink added.

"This study does not preclude potential studies in the future to assess its effectiveness in a more defined patient population," he said.

More information

There's more on heart failure at the U.S. National Library of Medicine.



SOURCES: John R. Teerlink, M.D., associate professor, medicine, Universiy of California, San Francisco; Randall Starling, M.D., director, heart failure and tranplantation, Cleveland Clinic; Christopher M. O'Connor, M.D., professor, medicine, Duke University, Durham, N.C.; Nov. 7, 2007, Journal of the American Medical Association


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Federal research plan to determine nanotech risks fails to deliver
7. States HMO Report Card Fails in Meaningful Evaluation of Health Care Quality and Ignores Affordability
8. Emergency Care for Heart Attacks, Pneumonia Fails to Meet Goals
9. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
10. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
11. Despite overeating, morbidly obese mice gain protection against diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Fails Against Heart Failure
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
Breaking Medicine Technology: